NEUROCRINE BIOSCIENCES INC Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments
NEUROCRINE BIOSCIENCES INC (NBIX) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments of $47.50 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-02-09.
Discontinued › Shareholders' Equity › Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments · last filed 2023-02-09
- NEUROCRINE BIOSCIENCES INC adjustments to additional paid in capital, equity component of convertible debt, subsequent adjustments for fiscal 2020 was $47.50M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt, Subsequent Adjustments 12 month |
|---|---|
| 2020-12-31 | $47.50M 10-K · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |